<!doctype html>
 
<!--[if lt IE 7]><html class="no-js ie6 oldie" lang="en"><![endif]-->
<!--[if IE 7]><html class="no-js ie7 oldie" lang="en"><![endif]-->
<!--[if IE 8]><html class="no-js ie8 oldie" lang="en"><![endif]-->
<!--[if gt IE 8]><!--><html class="no-js" lang="en"><!--<![endif]-->
 
<head>

	<!-- page specific -->
	
	<title>Written Authority Required Drugs 012-63060000</title>
	
	<!-- /page specific -->

	<meta charset="utf-8" />
	<meta http-equiv="X-UA-Compatible" content="IE=edge" />

	<meta name="DC.Coverage.jurisdiction" content="All" />
	<meta name="DC.Creator" content="Department of Human Services" />
	<meta name="DC.Format" scheme="IMT" content="text/html" />
	<meta name="DC.Language" scheme="RFC3066" content="en_AU" />
	<meta name="DC.Publisher" content="c=AU;o=Commonwealth of Australia;ou=Department of Human Services" />
	
	<meta name="format-detection" content="telephone=no" />

	<meta name="googlebot" content="noindex, nofollow" />
	<meta name="msnbot" content="noindex, nofollow" />
	<meta name="Slurp" content="noindex, nofollow" />
	
	<!-- mobile -->
	<meta name="HandheldFriendly" content="True" /> 
	<meta name="MobileOptimized" content="320" />
	<meta name="viewport" content="width=device-width, initial-scale=1.0" />
	<!-- /mobile -->
	

	<!-- For all browsers -->
	<link rel="stylesheet" href="../../supportingContent/css/styles.css" media="screen" />
	<link rel="stylesheet" href="../../supportingContent/css/print.css" media="print" />
	
	<script type="text/javascript" src="../../supportingContent/js/jquery.min.js"></script>
	<script type="text/javascript" src="../../supportingContent/js/application.js"></script>
		
	<!--[if lt IE 9]>
		<script type="text/javascript" src="../../supportingContent/js/html5shiv.js"></script>
		<script type="text/javascript" src="../../supportingContent/js/html5shiv-printshiv.js"></script>
	<![endif]-->
	
	<!--[if lt IE 9]>
		<script type="text/javascript" src="../../supportingContent/js/respond.js"></script>
		<link rel="stylesheet" href="../../supportingContent/css/ie.css" />
	<![endif]-->

<title> 012-63060000</title></head>

<body class="operational operational-home no-gutters">

<div class="accessibility-hidden">
	<a href="#navigation">Skip to navigation</a>
	<a href="#content">Skip to content</a>
</div>

<!-- Begin Header section -->
<div id="header">
	<div id="header-top">
		<div class="container">
			<div class="row">
				<div class="threecol">
					<a title="Services Australia" id="crest-top" href="http://www.servicesaustralia.gov.au/">
						<img alt="Australian Government - Services Australia" src="../../supportingContent/images/crest-top-new.png"/>
					</a>			
				</div>			
				<div class="ninecol last">
<!--				
				<div id="app-title">
					<span>Operational Blueprint</span>
				</div>
-->
					<div id="agency-nav">
						<ul class="clearfix">
							<li class="humanservices-gov-au"><a href="http://www.servicesaustralia.gov.au/">servicesaustralia.gov.au</a></li>
						</ul>
						<div id="top-stripe" class="colour-stripe">
							<span class="le-1 first">&nbsp;</span>
							<span class="le-2">&nbsp;</span>
							<span class="le-3">&nbsp;</span>
							<span class="le-4">&nbsp;</span>
							<span class="le-5">&nbsp;</span>
							<span class="le-6">&nbsp;</span>
							<span class="le-7">&nbsp;</span>
							<span class="le-8">&nbsp;</span>
							<span class="le-9">&nbsp;</span>
							<span class="le-10">&nbsp;</span>
							<span class="le-11">&nbsp;</span>
							<span class="le-12">&nbsp;</span>
							<span class="le-13">&nbsp;</span>
							<span class="le-14">&nbsp;</span>
							<span class="le-15">&nbsp;</span>
							<span class="le-16">&nbsp;</span>
							<span class="le-17">&nbsp;</span>
							<span class="le-18 last">&nbsp;</span>
						</div>
					</div>
				</div>
			</div>
		</div>
	</div>
	<div class="container">
		<div class="row">
			<div class="threecol">
				<a title="Services Australia" id="crest-middle" href="http://www.servicesaustralia.gov.au/">
					<img alt="Services Australia website" id="print-crest" src="../../supportingContent/images/print-crest.jpg"/>
					<img alt="Services Australia website" id="screen-crest" src="../../supportingContent/images/crest-middle-new.png"/>
				</a>
			</div>		
				
			<div class="ninecol last">
				<div class="global-nav-home clearfix" id="global-nav">
					<img alt="Services Australia website" id="mobile-crest" src="../../supportingContent/images/crest-mobile-new.png"/>
	
					<div id="global-nav-menu">
						<ul id="global-nav-links">
							<li class="first"><a href="../../home.html" shape="">Home</a></li>
							<li><a href="http://servicesaustralia.findnearest.com.au/" shape="">Find us</a></li>
							<li class="last"><a href="http://www.servicesaustralia.gov.au/customer/contact-us/" shape="">Contact us</a></li>
						</ul>
						<div class="search">
							<form method="get" action="/public/search/search.html"><input type="text" title="Search" onblur="if(this.value=='')this.value='search'" onfocus="if(this.value=='search')this.value=''" value="search" name="zoom_query" id="zoom_query"/><button type="submit" title="Search"><span>Search</span></button><input name='zoom_per_page' type="hidden" value="10" /></form>

						</div>
					</div>
				</div>		
			</div>		
		</div>
	</div>
</div>	
<!-- End Header section --> 
<!-- start pageData -->
<div class="container">
	<div class="row content-area">
		<div class="threecol">
			<a title="Services Australia" id="crest-bottom" href="http://www.servicesaustralia.gov.au/">
				<img alt="Australian Government - Services Australia" src="../../supportingContent/images/crest-bottom-new.png"/>
			</a>
			<!-- start pageDataNavLinks -->
			<div class="navigation clearfix" id="navigation">
				<ul>

					<li><a href="http://www.servicesaustralia.gov.au"> servicesaustralia.gov.au</a></li>
					<li><a href="../SiteMap/siteMap.html"> Site Map</a></li>
					<hr>
					<li><a href="../SiteMap/business-and-employers.html"> Business and employers</a></li>
					<li><a href="../SiteMap/carers.html"> Carers</a></li>
					<li><a href="../SiteMap/families.html"> Families</a></li>
					<li><a href="../SiteMap/health-professionals.html"> Health professionals</a></li>
					<li><a href="../SiteMap/help-in-an-emergency.html"> Help in an emergency</a></li>
					<li><a href="../SiteMap/indigenous-australians.html"> Indigenous Australians</a></li>
					<li><a href="../SiteMap/job-seekers.html"> Job seekers</a></li>
					<li><a href="../SiteMap/migrants-refugees-and-visitors.html"> Migrants, refugees & visitors</a></li>
					<li><a href="../SiteMap/older-australians.html"> Older Australians</a></li>
					<li><a href="../SiteMap/people-with-disability.html"> People with disability</a></li>
					<li><a href="../SiteMap/rural-and-remote-australians.html"> Remote & rural Australians</a></li>
					<li><a href="../SiteMap/separated-parents.html"> Separated parents</a></li>
					<li><a href="../SiteMap/students-and-trainees.html"> Students and trainees</a></li>
					<li><a href="../SiteMap/your-health.html"> Your health</a></li>
					<li><a href="../SiteMap/additional-products-and-services.html"> Additional products and services</a></li>
					<li><a href="../SiteMap/australians-overseas.html"> Australians overseas</a></li>
					<li><a href="../SiteMap/bereavement.html"> Bereavement</a></li>
					<li><a href="../SiteMap/ongoing-contact.html"> Change of circumstances</a></li>
					<li><a href="../SiteMap/compensation.html"> Compensation</a></li>
					<li><a href="../SiteMap/complaints-privacy-and-foi.html"> Complaints, privacy and Freedom of Information</a></li>
					<li><a href="../SiteMap/compliance-and-reviews.html"> Compliance & review</a></li>
					<li><a href="../SiteMap/debts.html"> Debts</a></li>
					<li><a href="../SiteMap/income-assests-and-rates-of-payment.html"> Income, assets and rates of payment</a></li>
					<li><a href="../SiteMap/initial-contact-general.html"> Initial contact & POI</a></li>
					<li><a href="../SiteMap/payment-delivery.html"> Payment delivery</a></li>
					<li><a href="../SiteMap/review-of-decision-and-appeals.html"> Review of decision & appeals</a></li>
					<li><a href="../SiteMap/self-service.html"> Self service</a></li>
					<li><a href="../SiteMap/specialist-manuals-and-system-tools.html"> Specialist manuals & system tools</a></li>
				</ul>
			</div>
			<!-- end pageDataNavLinks -->
		</div>		
	
		<div class="ninecol last">
			<div id="content">
				<!--  The actual page data now fits in here  -->
			
				<!-- start pageDataHeading -->
				<h1>Written Authority Required Drugs 012-63060000</h1>

				<!-- end pageDataHeading -->
				
				<!-- start pageDataContent -->
				<div id="bgtab" class="">
					
<div id="relatedMessagesDiv"></div>


					<div class="unitRight"><a href="javascript:expandCollapseSections()" id="toggleText" alt="Expand/Collapse all sections" title="Expand/Collapse all sections"><img src="../../supportingContent/images/icons/toggle_plus.gif"align="top" id="toggleImage"border="0" alt="Expand/Collapse all sections"width="16" height="16">Expand all</a></div><br><br>

					<body>
<UL id=tabs-primary><LI><A href="../health-professionals/012-63060000-01.html">Background</A></LI>
<LI><A href="../health-professionals/012-63060000-03.html">Process</A></LI>
<LI><A class="active students" href="../health-professionals/012-63060000-05.html">Resources</A></LI></UL><DIV id=topnav></DIV>
<DIV class=fullWidth>
</DIV>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_Contact_details class=anchor></A>
<H2 id=_Toc344898764>Contact details</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Pharmaceutical Benefits Scheme (PBS) - Complex Drugs Programs</P></DIV></DIV></DIV>
<P></P>
<DIV class=twisty>
<H2 id=_Toc344898764>Services Australia website</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P><A class=extwebsitelink href="https://www.servicesaustralia.gov.au/health-professionals/services/medicare/complex-authority-required-drugs" target=_blank>Written Authority Required Drugs</A></P></DIV></DIV></DIV>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_abatacept_Oren class=anchor></A>
<H2 id=_Toc344898764>abatacept (Orencia®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Abatacept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required (Section 100 only).</P>
<P>Providing the patient meets specific restriction criteria, abatacept is subsidised for the treatment of: </P>
<UL>
<LI>rheumatoid arthritis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_adalimumab_Hum01 class=anchor></A>
<H2 id=_Toc344898764>adalimumab (Humira®/Amgevita®/Hadlima®/Hyrimoz®/Idacio®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Adalimumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required (Section 100 only).</P>
<P>Providing the patient meets specific restriction criteria, adalimumab is subsidised for the treatment of:</P>
<UL>
<LI>ankylosing spondylitis</LI>
<LI>Crohn's disease</LI>
<UL>
<LI>adult</LI>
<LI>paediatric</LI></UL>
<LI>fistulising Crohn's disease</LI>
<LI>hidradenitis suppurativa</LI>
<LI>juvenile idiopathic arthritis</LI>
<LI>psoriatic arthritis</LI>
<LI>rheumatoid arthritis</LI>
<LI>severe chronic plaque psoriasis</LI>
<UL>
<LI>adult</LI></UL>
<LI>ulcerative colitis</LI>
<UL>
<LI>adult</LI>
<LI>paediatric</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_aflibercept_Ey class=anchor></A>
<H2 id=_Toc344898764>aflibercept (Eylea®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Aflibercept is a Section 85 listed pharmaceutical benefit. </P>
<P>Providing the patient meets specific restriction criteria, aflibercept is subsidised for the treatment of:</P>
<UL>
<LI>diabetic macular oedema </LI>
<LI>retinal vein occlusion with macular oedema</LI>
<LI>subfoveal choroidal neovascularisation due to: </LI>
<UL>
<LI>age related macular degeneration</LI>
<LI>pathologic myopia</LI>
<LI>rare causes</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_ambrisentan_Vo class=anchor></A>
<H2 id=_Toc344898764>ambrisentan (Volibris®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Ambrisentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, ambrisentan is subsidised for the treatment of:</P>
<UL>
<LI>pulmonary arterial hypertension</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_armodafinil_Nu01 class=anchor></A>
<H2 id=_Toc344898764>armodafinil (Nuvigil®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Armodafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets the specific restriction criteria, armodafinil is subsidised for the treatment of: </P>
<UL>
<LI>narcolepsy</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_azacitidine_Vi class=anchor></A>
<H2 id=_Toc344898764>azacitidine (Vidaza®/Azadine®/Celazadine®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Azacitidine is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, azacitidine is subsidised for the treatment of:</P>
<UL>
<LI>myelodysplastic syndrome</LI>
<LI>chronic myelomonocytic leukaemia</LI>
<LI>acute myeloid leukaemia</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_baricitinib_Ol01 class=anchor></A>
<H2 id=_Toc344898764>baricitinib (Olumiant®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Baricitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, baricitinib is subsidised for the treatment of:</P>
<UL>
<LI>rheumatoid arthritis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_benralizumab_F class=anchor></A>
<H2 id=_Toc344898764>benralizumab (Fasenra®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Benralizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, benralizumab is subsidised for the treatment of:</P>
<UL>
<LI>severe asthma</LI>
<UL>
<LI>adult</LI>
<LI>adolescent</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_bevacizumab_Av01 class=anchor></A><A name=bp05_L2GT_blinatumomab_B class=anchor></A>
<H2 id=_Toc344898764>blinatumomab (Blincyto®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Blinatumomab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, blinatumomab is subsidised for the treatment of:</P>
<UL>
<LI>acute lymphoblastic leukaemia</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_bosentan_monohy class=anchor></A>
<H2 id=_Toc344898764>bosentan monohydrate (Tracleer®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Bosentan monohydrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, bosentan monohydrate is subsidised for the treatment of:</P>
<UL>
<LI>pulmonary arterial hypertension</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_brentuximab_Ad class=anchor></A>
<H2 id=_Toc344898764>brentuximab vedotin (Adcetris®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Brentuximab vedotin is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. </P>
<P>Providing the patient meets the specific restriction criteria, brentuximab is subsidised for the treatment of:</P>
<UL>
<LI>CD30 positive systemic anaplastic large cell lymphoma</LI>
<LI>relapsed or refractory Hodgkin lymphoma</LI>
<LI>cutaneous T-cell lymphoma</LI>
<LI>peripheral T-cell lymphoma</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_brolucizumab_B class=anchor></A>
<H2 id=_Toc344898764>brolucizumab (Beovu®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>brolucizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets the specific restriction criteria, brolucizumab is subsidised for the treatment of:</P>
<UL>
<LI>age related macular degeneration (AMD)</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_certolizumab_pe class=anchor></A>
<H2 id=_Toc344898764>certolizumab pegol (Cimzia®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Certolizumab pegol is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets the specific restriction criteria, certolizumab is subsidised for the treatment of:</P>
<UL>
<LI>rheumatoid arthritis</LI>
<LI>ankylosing spondylitis</LI>
<LI>psoriatic arthritis</LI>
<LI>non-radiographic axial spondyloarthritis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_crizotinib_Xal class=anchor></A>
<H2 id=_Toc344898764>crizotinib (Xalkori®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Crizotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, crizotinib is subsidised for the treatment of:</P>
<UL>
<LI>Stage IIIB or Stage IV non-small-cell lung cancer</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_dasatinib_Spry class=anchor></A>
<H2 id=_Toc344898764>dasatinib (Sprycel®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Dasatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, dasatinib is subsidised for the treatment of:</P>
<UL>
<LI>acute lymphoblastic leukaemia </LI>
<LI>chronic myeloid leukaemia </LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_dexamethasone_i class=anchor></A>
<H2 id=_Toc344898764>dexamethasone implant (Ozurdex®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Dexamethasone is a Section 85 listed pharmaceutical benefit. </P>
<P>Providing the patient meets the specific restriction criteria, dexamethasone implant is subsidised for the treatment of:</P>
<UL>
<LI>diabetic macular oedema</LI>
<LI>retinal vein occlusion macular oedema</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_dupilumab_Dupi class=anchor></A>
<H2 id=_Toc344898764>dupilumab (Dupixent®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Dupilumab is listed under Section 100 – Highly Specialised Drugs Program, and is administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets the specific restriction criteria, dupilumab is subsidised for the treatment of:</P>
<UL>
<LI>severe asthma</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_eculizumab_Sol class=anchor></A>
<H2 id=_Toc344898764>eculizumab (Soliris®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Eculizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets the specific restriction criteria, eculizumab is subsidised for the treatment of:</P>
<UL>
<LI>atypical haemolytic uraemic syndrome</LI>
<LI>paroxysmal nocturnal haemoglobinuria</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_elexacaftortez class=anchor></A>
<H2 id=_Toc344898764>elexacaftor+tezacaftor+ivacaftor (Trikafta®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Elexacaftor+tezacaftor+ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets the specific restriction criteria, elexacaftor+tezacaftor+ivacaftor is subsidised for the treatment of:</P>
<UL>
<LI>cystic fibrosis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_eltrombopag_Re class=anchor></A>
<H2 id=_Toc344898764>eltrombopag (Revolade®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Eltrombopag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, eltrombopag is subsidised for the treatment of:</P>
<UL>
<LI>idiopathic thrombocytopenic purpura </LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_entrectinib_Ro class=anchor></A>
<H2 id=_Toc344898764>entrectinib (Rozlytrek®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Entrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, entrectinib is subsidised for the treatment of:</P>
<UL>
<LI>Stage IIIB or Stage IV non-small-cell lung cancer </LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_epoprostenol_so class=anchor></A>
<H2 id=_Toc344898764>epoprostenol sodium (Flolan®/Veletri®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Epoprostenol sodium is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, epoprostenol sodium is subsidised for the treatment of:</P>
<UL>
<LI>pulmonary arterial hypertension</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_etanercept_Enb class=anchor></A>
<H2 id=_Toc344898764>etanercept (Enbrel®/Brenzys®) </H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Etanercept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required (Section 100 only).</P>
<P>Providing the patient meets specific restriction criteria, etanercept is subsidised for the treatment of:</P>
<UL>
<LI>ankylosing spondylitis</LI>
<LI>juvenile idiopathic arthritis</LI>
<LI>psoriatic arthritis</LI>
<LI>rheumatoid arthritis</LI>
<LI>severe chronic plaque psoriasis </LI>
<UL>
<LI>adults</LI>
<LI>paediatric</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_golimumab_Simp class=anchor></A>
<H2 id=_Toc344898764>golimumab (Simponi®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Golimumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria golimumab is subsidised for the treatment of:</P>
<UL>
<LI>ankylosing spondylitis</LI>
<LI>ulcerative colitis</LI>
<UL>
<LI>adult</LI></UL>
<LI>psoriatic arthritis</LI>
<LI>rheumatoid arthritis</LI>
<LI>non-radiographic axial spondyloarthritis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_guselkumab_Tre class=anchor></A>
<H2 id=_Toc344898764>guselkumab (Tremfya®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>guselkumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, guselkumab is subsidised for the treatment of:</P>
<UL>
<LI>Psoriatic arthritis</LI>
<LI>Severe chronic plaque psoriasis</LI>
<UL>
<LI>adult</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_iloprost_tromet class=anchor></A>
<H2 id=_Toc344898764>iloprost trometamol (Ventavis®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Iloprost trometamol is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, iloprost trometamol is subsidised for the treatment of:</P>
<UL>
<LI>pulmonary arterial hypertension </LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_imatinib_Glive class=anchor></A>
<H2 id=_Toc344898764>imatinib (Glivec®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Imatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, imatinib is an agent subsidised for the treatment of:</P>
<UL>
<LI>chronic myeloid leukaemia </LI>
<LI>gastrointestinal stromal tumour</LI>
<LI>acute lymphoblastic leukaemia</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_infliximab_Rem class=anchor></A>
<H2 id=_Toc344898764>infliximab (Remicade®/Inflectra®/Renflexis®/Remsima®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Infliximab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, infliximab is subsidised for the treatment of:</P>
<UL>
<LI>ankylosing spondylitis</LI>
<LI>Crohn's disease</LI>
<UL>
<LI>adults</LI>
<LI>paediatric</LI></UL>
<LI>psoriatic arthritis</LI>
<LI>rheumatoid arthritis</LI>
<LI>severe chronic plaque psoriasis </LI>
<UL>
<LI>adults</LI></UL>
<LI>ulcerative colitis</LI>
<UL>
<LI>adult</LI>
<LI>paediatric</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_ivacaftor_Kaly class=anchor></A>
<H2 id=_Toc344898764>ivacaftor (Kalydeco®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets the specific restriction criteria, ivacaftor is subsidised for the treatment of:</P>
<UL>
<LI>cystic fibrosis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_ixekizumab_Tal class=anchor></A>
<H2 id=_Toc344898764>ixekizumab (Taltz®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Ixekizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets the specific restriction criteria, ixekizumab is subsidised for the treatment of:</P>
<UL>
<LI>ankylosing spondylitis</LI>
<LI>psoriatic arthritis</LI>
<LI>severe chronic plaque psoriasis</LI>
<UL>
<LI>adult</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_lanadelumab_Ta class=anchor></A>
<H2 id=_Toc344898764>lanadelumab (Takhzyro®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Lanadelumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, lanadelumab is subsidised for the treatment of:</P>
<UL>
<LI>hereditary angioedema type 1 or 2</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_lapatinib_Tyke class=anchor></A>
<H2 id=_Toc344898764>lapatinib (Tykerb®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Lapatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, lapatinib is subsidised for the treatment of:</P>
<UL>
<LI>metastatic breast cancer</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_larotrectinib_ class=anchor></A>
<H2 id=_Toc344898764>larotrectinib (Vitrakvi®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Larotrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, larotrectinib is subsidised for the treatment of:</P>
<UL>
<LI>solid tumours that are confirmed to be neurotrophic tropomyosin receptor kinase (NTRK) gene fusion positive</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_lenalidomide_R class=anchor></A>
<H2 id=_Toc344898764>lenalidomide (Revlimid®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Lenalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, lenalidomide is subsidised for the treatment of:</P>
<UL>
<LI>multiple myeloma</LI>
<LI>myelodysplastic syndrome</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_lumacaftorivac class=anchor></A>
<H2 id=_Toc344898764>lumacaftor+ivacaftor (Orkambi®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Lumacaftor+Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets the specific restriction criteria, lumacaftor+ivacaftor is subsidised for the treatment of:</P>
<UL>
<LI>cystic fibrosis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_macitentan_Ops class=anchor></A>
<H2 id=_Toc344898764>macitentan (Opsumit®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Macitentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, macitentan is subsidised for the treatment of:</P>
<UL>
<LI>pulmonary arterial hypertension</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_mepolizumab_Nu class=anchor></A>
<H2 id=_Toc344898764>mepolizumab (Nucala®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Mepolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, mepolizumab is subsidised for the treatment of:</P>
<UL>
<LI>severe asthma</LI>
<UL>
<LI>adult</LI>
<LI>adolescent</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_midostaurin_Ry class=anchor></A>
<H2 id=_Toc344898764>midostaurin (Rydapt®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Midostaurin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, midostaurin is subsidised for the treatment of:</P>
<UL>
<LI>acute myeloid leukaemia</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_modafinil_Moda class=anchor></A>
<H2 id=_Toc344898764>modafinil (Modavigil®/Modafin®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Modafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, modafinil is subsidised for the treatment of:</P>
<UL>
<LI>narcolepsy</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_nilotinib_Tasi class=anchor></A>
<H2 id=_Toc344898764>nilotinib (Tasigna®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Nilotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, nilotinib is subsidised for the treatment of:</P>
<UL>
<LI>chronic myeloid leukaemia</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_nintedanib_Ofe class=anchor></A>
<H2 id=_Toc344898764>nintedanib (Ofev®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Nintedanib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, nintedanib is subsidised for the treatment of:</P>
<UL>
<LI>idiopathic pulmonary fibrosis</LI>
<LI>progressive fibrosing interstitial lung disease</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_nusinersen_Spi class=anchor></A>
<H2 id=_Toc344898764>nusinersen (Spinraza®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Nusinersen is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, nusinersen is subsidised for the treatment of:</P>
<UL>
<LI>spinal muscular atrophy </LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_omalizumab_Xol class=anchor></A>
<H2 id=_Toc344898764>omalizumab (Xolair®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Omalizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, omalizumab is subsidised for the treatment of:</P>
<UL>
<LI>severe asthma</LI>
<LI>chronic spontaneous urticaria</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_onasemnogene_ab class=anchor></A>
<H2 id=_Toc344898764>onasemnogene abeparvovec (Zolgensma®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Onasemnogene abeparvovec is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, onasemnogene abeparvovec is subsidised for the treatment of:</P>
<UL>
<LI>spinal muscular atrophy</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_pasireotide_Si class=anchor></A>
<H2 id=_Toc344898764>pasireotide (Signifor LAR®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Pasireotide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority is required.</P>
<P>Providing the patient meets specific restriction criteria, pasireotide is subsidised for the treatment of:</P>
<UL>
<LI>acromegaly</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_pegvisomant_So class=anchor></A>
<H2 id=_Toc344898764>pegvisomant (Somavert®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Pegvisomant is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority is required.</P>
<P>Providing the patient meets specific restriction criteria, pegvisomant is subsidised for the treatment of:</P>
<UL>
<LI>acromegaly</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_pembrolizumab_ class=anchor></A>
<H2 id=_Toc344898764>pembrolizumab (Keytruda®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Pembrolizumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. </P>
<P>Providing the patient meets specific restriction criteria, pembrolizumab is subsidised for the treatment of:</P>
<UL>
<LI>relapsed or refractory Hodgkin lymphoma</LI>
<LI>primary mediastinal B-Cell lymphoma</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_pertuzumab_Per class=anchor></A>
<H2 id=_Toc344898764>pertuzumab (Perjeta®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Pertuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, pertuzumab is subsidised for the treatment of:</P>
<UL>
<LI>metastatic breast cancer</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_pirfenidone_Es class=anchor></A>
<H2 id=_Toc344898764>pirfenidone (Esbriet®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Pirfenidone is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, pirfenidone is subsidised for the treatment of:</P>
<UL>
<LI>idiopathic pulmonary fibrosis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_polylactic_acid class=anchor></A>
<H2 id=_Toc344898764>polylactic acid (Sculptra®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Pirfenidone is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, polylactic acid is subsidised for the treatment of:</P>
<UL>
<LI>severe facial lipoatrophy</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_pomalidomide_P class=anchor></A>
<H2 id=_Toc344898764>pomalidomide (Pomalyst®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Pomalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, pomalidomide is subsidised for the treatment of:</P>
<UL>
<LI>multiple myeloma</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_ponatinib_Iclu class=anchor></A>
<H2 id=_Toc344898764>ponatinib (Iclusig®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Ponatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, ponatinib is an agent subsidised for the treatment of:</P>
<UL>
<LI>chronic myeloid leukaemia </LI>
<LI>acute lymphoblastic leukaemia </LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_ranibizumab_Lu class=anchor></A>
<H2 id=_Toc344898764>ranibizumab (Lucentis®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Ranibizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. </P>
<P>Providing the patient meets specific restriction criteria, ranibizumab is subsidised for the treatment of:</P>
<UL>
<LI>diabetic macular oedema </LI>
<LI>retinal vein occlusion with macular oedema</LI>
<LI>subfoveal choroidal neovascularisation due to:</LI>
<UL>
<LI>age related macular degeneration </LI>
<LI>pathologic myopia </LI>
<LI>rare causes </LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_ravulizumab_Ul class=anchor></A>
<H2 id=_Toc344898764>ravulizumab (Ultomiris®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Ravulizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, ravulizumab is subsidised for the treatment of:</P>
<UL>
<LI>paroxysmal nocturnal haemoglobinuria</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_riociguat_Adem class=anchor></A>
<H2 id=_Toc344898764>riociguat (Adempas®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Riociguat is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, riociguat is subsidised for the treatment of:</P>
<UL>
<LI>pulmonary arterial hypertension </LI>
<LI>chronic thromboembolic pulmonary hypertension</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_ripretinib_Qin class=anchor></A>
<H2 id=_Toc344898764>ripretinib (Qinlock®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Ripretinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, ripretinib is subsidised for the treatment of:</P>
<UL>
<LI>gastrointestinal stromal tumour</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_risankizumab_S class=anchor></A>
<H2 id=_Toc344898764>risankizumab (Skyrizi®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Risankizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, risankizumab is subsidised for the treatment of:</P>
<UL>
<LI>severe chronic plaque psoriasis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_risdiplam_Evry class=anchor></A>
<H2 id=_Toc344898764>risdiplam (Evrysidi®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Risdiplam is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, risdiplam is subsidised for the treatment of:</P>
<UL>
<LI>spinal muscular atrophy</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_rituximab_Mabt class=anchor></A>
<H2 id=_Toc344898764>rituximab (Riximyo®/Truxima®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Rituximab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, rituximab is subsidised for the treatment of:</P>
<UL>
<LI>rheumatoid arthritis</LI>
<LI>polyangiitis</LI>
<LI>severe active granulomatosis with polyangiitis</LI>
<LI>severe active microscopic polyangiitis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_romiplostim_Np class=anchor></A>
<H2 id=_Toc344898764>romiplostim (Nplate®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Romiplostim is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, romiplostim is subsidised for the treatment of:</P>
<UL>
<LI>idiopathic thrombocytopenic purpura</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_ruxolitinib_Ja class=anchor></A>
<H2 id=_Toc344898764>ruxolitinib (Jakavi®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Ruxolitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, ruxolitinib is subsidised for the treatment of: </P>
<UL>
<LI>myelofibrosis </LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_secukinumab_Co class=anchor></A>
<H2 id=_Toc344898764>secukinumab (Cosentyx®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Secukinumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, secukinumab is subsidised for the treatment of:</P>
<UL>
<LI>ankylosing spondylitis</LI>
<LI>severe chronic plaque psoriasis</LI>
<UL>
<LI>adult</LI></UL>
<LI>psoriatic arthritis</LI>
<LI>non-radiographic axial spondyloarthritis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_sildenafil_citr class=anchor></A>
<H2 id=_Toc344898764>sildenafil citrate (Revatio®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Sildenafil citrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, sildenafil citrate is subsidised for the treatment of: </P>
<UL>
<LI>pulmonary arterial hypertension</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_somatropin_Gen class=anchor></A>
<H2 id=_Toc344898764>somatropin (Genotropin®/Norditropin®/Nutropin®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Somatropin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, somatropin is subsidised for the treatment of </P>
<UL>
<LI>growth hormone deficiency</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_sonidegib_Odom class=anchor></A>
<H2 id=_Toc344898764>sonidegib (Odomzo®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Sonidegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, sonidegib is subsidised for the treatment of:</P>
<UL>
<LI>basal cell carcinoma</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_sunitinib_malat class=anchor></A>
<H2 id=_Toc344898764>sunitinib malate (Sutent®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Sunitinib malate is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, sunitinib malate is subsidised for the treatment of: </P>
<UL>
<LI>malignant gastrointestinal stromal tumour</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_tadalafil_Adci class=anchor></A>
<H2 id=_Toc344898764>tadalafil (Adcirca®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Tadalafil is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, tadalafil is used to treat patients with:</P>
<UL>
<LI>pulmonary arterial hypertension</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_teduglutide_Re class=anchor></A>
<H2 id=_Toc344898764>teduglutide (Revestive®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Teduglutide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, teduglutide is subsidised for the treatment of:</P>
<UL>
<LI>short bowel syndrome with intestinal failure</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_tezacaftorivac class=anchor></A>
<H2 id=_Toc344898764>tezacaftor+ivacaftor (Symdeko®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Tezacaftor+Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets the specific restriction criteria, tezacaftor+ivacaftor is subsidised for the treatment of:</P>
<UL>
<LI>cystic fibrosis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_tildrakizumab_ class=anchor></A>
<H2 id=_Toc344898764>tildrakizumab (Ilumya®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Tildrakizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, tildrakizumab is subsidised for the treatment of:</P>
<UL>
<LI>severe chronic plaque psoriasis</LI>
<UL>
<LI>adult</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_tocilizumab_Ac class=anchor></A>
<H2 id=_Toc344898764>tocilizumab (Actemra®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Tocilizumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through PBS Complex Drugs team.</P>
<P>Public and private hospital authority required (section 100 listing only).</P>
<P>Providing the patient meets specific restriction criteria, tocilizumab is subsidised for the treatment of:</P>
<UL>
<LI>rheumatoid arthritis</LI>
<LI>systemic juvenile idiopathic arthritis</LI>
<LI>juvenile idiopathic arthritis</LI>
<LI>giant cell arteritis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_tofacitinib_Xe class=anchor></A>
<H2 id=_Toc344898764>tofacitinib (Xeljanz®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Tofacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, tofacitinib is subsidised for the treatment of: </P>
<UL>
<LI>psoriatic arthritis </LI>
<LI>rheumatoid arthritis</LI>
<LI>ulcerative colitis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_trastuzumab_emt class=anchor></A>
<H2 id=_Toc344898764>trastuzumab emtansine (Kadcyla®/Herceptin®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Trastuzumab emtansine is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, trastuzumab emtansine is subsidised for the treatment of:</P>
<UL>
<LI>metastatic breast cancer </LI>
<LI>early human epidermal growth factor receptor 2 positive breast cancer</LI>
<LI>gastric cancer </LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_upadacitinib_R class=anchor></A>
<H2 id=_Toc344898764>upadacitinib (Rinvoq®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Upadacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, upadacitinib is subsidised for the treatment of:</P>
<UL>
<LI>ankylosing spondylitis</LI>
<LI>psoriatic arthritis</LI>
<LI>rheumatoid arthritis</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_ustekinumab_St class=anchor></A>
<H2 id=_Toc344898764>ustekinumab (Stelara®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Ustekinumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required (section 100 listing only).</P>
<P>Providing the patient meets specific restriction criteria, ustekinumab is subsidised for the treatment of:</P>
<UL>
<LI>severe chronic plaque psoriasis </LI>
<UL>
<LI>adult</LI></UL>
<LI>psoriatic arthritis</LI>
<LI>crohn's disease </LI>
<UL>
<LI>adult</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_vedolizumab_En class=anchor></A>
<H2 id=_Toc344898764>vedolizumab (Entyvio®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Vedolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Public and private hospital authority required.</P>
<P>Providing the patient meets specific restriction criteria, vedolizumab is subsidised for the treatment of:</P>
<UL>
<LI>crohn's disease</LI>
<UL>
<LI>adult</LI></UL>
<LI>ulcerative colitis</LI>
<UL>
<LI>adult</LI></UL></UL></DIV></DIV></DIV>
<UL></UL>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_vismodegib_Eri class=anchor></A>
<H2 id=_Toc344898764>vismodegib (Erivedge®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Vismodegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, vismodegib is subsidised for the treatment of:</P>
<UL>
<LI>basal cell carcinoma</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<DIV class=twisty><A name=bp05_L2GT_vorinostat_Zol class=anchor></A>
<H2 id=_Toc344898764>vorinostat (Zolinza®)</H2>
<DIV class=collapsible_container>
<DIV class=block>
<P>Vorinostat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</P>
<P>Providing the patient meets specific restriction criteria, vorinostat is subsidised for the treatment of:</P>
<UL>
<LI>cutaneous T-cell lymphoma</LI></UL></DIV></DIV></DIV>
<UL></UL>
<P></P>
<P></P>
<P></P>
<P></P>
<P></P>

				</div>
				<!-- end primary tab container -->
				
				<!-- end pageDataContent -->
			</div>
		</div>
	</div>
</div>
<!-- end pageData -->


	<!-- start footer -->
<div id="footer">
	<div id="bottom-stripe">
		<div class="container">
			<div class="row colour-stripe">
				<span class="le-1 first">&nbsp;</span>
				<span class="le-2">&nbsp;</span>
				<span class="le-3">&nbsp;</span>
				<span class="le-4">&nbsp;</span>
				<span class="le-5">&nbsp;</span>
				<span class="le-6">&nbsp;</span>
				<span class="le-7">&nbsp;</span>
				<span class="le-8">&nbsp;</span>
				<span class="le-9">&nbsp;</span>
				<span class="le-10">&nbsp;</span>
				<span class="le-11">&nbsp;</span>
				<span class="le-12">&nbsp;</span>
				<span class="le-13">&nbsp;</span>
				<span class="le-14">&nbsp;</span>
				<span class="le-15">&nbsp;</span>
				<span class="le-16">&nbsp;</span>
				<span class="le-17">&nbsp;</span>
				<span class="le-18 last">&nbsp;</span>
			</div>
		</div> 
	</div>
	<div class="container">
		<div class="row" id="sub-footer">
			<ul>
				<li>Services Australia <acronym title="Australian Business Number">ABN</acronym> 90&nbsp;794&nbsp;605&nbsp;008&nbsp;</li>
			</ul>
		</div>
	</div>
</div>
	<!-- end footer -->
	
	<!-- start urchinTracker -->
	<script type="text/javascript" src="../../supportingContent/js/urchin.js"></script>
	<script type="text/javascript">if (typeof window.error404 === "undefined") { urchinTracker(); }</script>
	<!-- end urchinTracker -->

</body>
</html>